Early Changes in [18F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts
We investigated the potential use of [18F]FDG PET as a response biomarker for PI3K pathway targeting therapies in two HER-2-overexpressing cancer models. Methods. CD-1 nude mice were inoculated with HER-2-overexpressing JIMT1 (trastuzumab-resistant) or SKOV3 (trastuzumab-sensitive) human cancer cell...
Saved in:
Main Authors: | Yanina Dockx, Christel Vangestel, Tim Van den Wyngaert, Manon Huizing, Sven De Bruycker, Patrick Pauwels, Steven Staelens, Sigrid Stroobants |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-01-01
|
Series: | Molecular Imaging |
Online Access: | http://dx.doi.org/10.1155/2021/5594514 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Single-Photon Emission Computed Tomographic Imaging of the Early Time Course of Therapy-Induced Cell Death Using Technetium 99m Tricarbonyl His-Annexin A5 in a Colorectal Cancer Xenograft Model
by: Christel Vangestel, et al.
Published: (2012-03-01) -
Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI
by: Paul J. Akhenblit PhD, et al.
Published: (2016-04-01) -
mTOR Inhibition: From Aging to Autism and Beyond
by: Matt Kaeberlein
Published: (2013-01-01) -
The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas
by: Pinelopi Argyriou, et al.
Published: (2012-01-01) -
The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence
by: Goran B. Klintmalm, et al.
Published: (2014-01-01)